ANDA 207481, held by Amneal. Methylprednisolone.
As of Nov 16, 2026, ANDA 207481 (Methylprednisolone), held by Amneal, was first approved by FDA on Sep 21, 2021, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 21, 2021 | Original application | Approved | None posted |
| Methylprednisolone4MG · tablet;oral | Methylprednisolone | Discontinued |
| Methylprednisolone8MG · tablet;oral | Methylprednisolone | Discontinued |
| Methylprednisolone16MG · tablet;oral | Methylprednisolone | Discontinued |
| Methylprednisolone32MG · tablet;oral | Methylprednisolone | Discontinued |
| Sep 25, 2024 | Supplement 1Labeling · Standard review | Approved | None posted |
| Sep 21, 2021 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters